bioRxiv · 10.1101/2021.05.08.443146
Foldamers Reveal and Validate Novel Therapeutic Targets Associated with Toxic α-Synuclein Self-Assembly
Abstract
Parkinsons disease (PD) is a progressive neurodegenerative disorder for which there is no successful prevention or intervention. The pathological hallmark for PD involves the self-assembly of functional Alpha-Synuclein (S) into non-functional amyloid structures. One of the potential therapeutic interventions against PD is the effective inhibition of S aggregation. However, the bottleneck towards achieving this goal is the identification of S domains/sequences that are essential for aggregation. Using a protein mimetic approach, we have identified S sequences-based novel targets that are essential for aggregation and will have significant therapeutic implications. An extensive array of in vitro, ex vivo, and in vivo assays was utilized to validate S sequences and their structural characteristics that are essential for aggregation and propagation of PD phenotypes. The study aids in developing significant mechanistic and therapeutic insights into various facets of S aggregation, which will pave the way for novel and effective treatments for PD.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ahmed, J., Fitch, T. C., Donnelly, C. M., Joseph, J. A., Bassil, M. M., Son, A., Zhang, C., Ledreux, A., Horowitz, S., Qin, Y., Paredes, D., Kumar, S.. 2021-05-08. Foldamers Reveal and Validate Novel Therapeutic Targets Associated with Toxic α-Synuclein Self-Assembly. https://doi.org/10.1101/2021.05.08.443146
Cite the original work for its findings. Save a collection to share your selection of sources.